Patients anxious about DMARDs and COVID-19 risk

Patients with rheumatic diseases are concerned about their medications increasing the risk of COVID-19 disease, particularly those on combination csDMARDs or a b/tsDMARD, Australian research shows. A survey of 550 patients at the Monash Health Department of Rheumatology Department found...

Patients with rheumatic diseases are concerned about their medications increasing the risk of COVID-19 disease, particularly those on combination csDMARDs...

Education

Flexible rheumatology training gives ‘work-life balance’ without job sharing

A pilot program of flexible training for advanced rheumatology trainees has been a great success in providing work-life balance without the need to 'job share'. One of the program leads Associate Professor Ana Ananda told the limbic that despite the complications...

A pilot program of flexible training for advanced rheumatology trainees has been a great success in providing work-life balance without...

Education

Rheumatologist advice key to overcoming methotrexate fears and misconceptions

Rheumatologists are the most influential source of information about methotrexate for patients with rheumatoid arthritis and the most likely to provide positive information to overcome myths and misconceptions about its safety, research shows. For some patients the fear of potential adverse...

Rheumatologists are the most influential source of information about methotrexate for patients with rheumatoid arthritis and the most likely to...

Lupus

Lupus hopes dashed for ustekinumab after Phase 3 trial discontinued

The high expectations for the anti-IL 12/23 antibody ustekinumab (Stelara) in SLE based on Phase 2 trial results have not been borne out in larger Phase 3 studies. Manufacturer Janssen has announced it is discontinuing the Phase 3 LOTUS study...

The high expectations for the anti-IL 12/23 antibody ustekinumab (Stelara) in SLE based on Phase 2 trial results have not...